Spots Global Cancer Trial Database for lymphoid leukemia
Every month we try and update this database with for lymphoid leukemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Safety of Romiplostim (Nplate®) Following UCBT | NCT02046291 | Hematologic Mal... | Romiplostim | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| My-HyperCVAD in the Treatment of Relapsed Refractory Adult Acute Lymphoid Leukemia | NCT00801580 | Lymphoid Leukem... | doxorubicin lip... | 18 Years - | University of Bologna | |
| Oshadi D & Oshadi R Combined With Salvage Chemotherapy for Relapsed Acute Myeloid Leukemia or Lymphoid Leukemia Patients | NCT02462265 | Acute Myeloid L... Lymphoid Leukem... | Oshadi D & Osha... salvage therapy... | 18 Years - | Oshadi Drug Administration | |
| Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS) | NCT03970096 | Acute Leukemia Acute Lymphobla... Acute Myeloid L... Myelodysplastic... | Total-Body Irra... Thiotepa Fludarabine Tacrolimus Allogeneic CD34... Methotrexate Cyclophosphamid... Peripheral Bloo... Cyclosporine Sirolimus Busulfan Bone Marrow Asp... Echocardiograph... Multigated Acqu... Biospecimen Col... | 1 Year - 60 Years | Fred Hutchinson Cancer Center | |
| Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis | NCT02593123 | Hodgkin's Lymph... Lymphoid Leukem... Lymphoma Leukemia Myeloma Acute Lymphocyt... Non Hodgkin Lym... Chronic Lymphoc... Multiple Myelom... Chronic Myeloge... Myelodysplastic... Recurrent Acute... Recurrent Hodgk... Recurrent Non-H... Recurrent Plasm... Recurrent Chron... Recurrent Chron... Acute Myelogeno... | mycophenolate m... Sargramostim Filgrastim | 18 Years - 74 Years | Virginia Commonwealth University | |
| My-HyperCVAD in the Treatment of Relapsed Refractory Adult Acute Lymphoid Leukemia | NCT00801580 | Lymphoid Leukem... | doxorubicin lip... | 18 Years - | University of Bologna | |
| 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome | NCT03670966 | Acute Lymphobla... Acute Myeloid L... Acute Myeloid L... Chronic Myelomo... Myelodysplastic... Recurrent Acute... Recurrent Acute... Refractory Acut... Refractory Acut... Recurrent Mixed... Refractory Mixe... Hematopoietic a... | Astatine At 211... Cyclophosphamid... Total-Body Irra... Peripheral Bloo... Bone Marrow Tra... Mycophenolate M... Recombinant Gra... Fludarabine Pho... Tacrolimus Bone Marrow Asp... Biospecimen Col... | 18 Years - 75 Years | Fred Hutchinson Cancer Center | |
| Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy | NCT00469729 | Hematologic Mal... Acute Myeloid L... Lymphoid Leukem... Chronic Myeloid... Hodgkin's Disea... Non-Hodgkin's L... Myelodysplastic... | StemEx® | 12 Years - 55 Years | Gamida Cell -Teva Joint Venture Ltd. | |
| Arsenic Trioxide for Induction Therapy of Adult Patients With Leukemia | NCT00006092 | Leukemia | Arsenic Trioxid... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas | NCT03277729 | Recurrent B-Cel... Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Refractory B-Ce... Refractory Diff... Refractory Foll... Refractory Lymp... Refractory Mant... Refractory Tran... Recurrent Trans... Recurrent Trans... Refractory Marg... Refractory Tran... Refractory Tran... Recurrent Small... Refractory Chro... Refractory Smal... Recurrent Centr... Refractory Cent... | Chimeric Antige... Cyclophosphamid... Laboratory Biom... Leukapheresis Fludarabine Pho... | 18 Years - | Fred Hutchinson Cancer Center | |
| Outcomes in Pediatric and Young Adult B-Cell Malignancies After Commercially Available Immunotherapy | NCT05865301 | Lymphoid Leukem... | Questionnaire f... | - 26 Years | Stanford University | |
| Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS) | NCT03970096 | Acute Leukemia Acute Lymphobla... Acute Myeloid L... Myelodysplastic... | Total-Body Irra... Thiotepa Fludarabine Tacrolimus Allogeneic CD34... Methotrexate Cyclophosphamid... Peripheral Bloo... Cyclosporine Sirolimus Busulfan Bone Marrow Asp... Echocardiograph... Multigated Acqu... Biospecimen Col... | 1 Year - 60 Years | Fred Hutchinson Cancer Center | |
| Biobehavioral Intervention to Enhance Hematopoietic Stem Cell Transplant Recovery | NCT02955043 | Hodgkin Lymphom... Non-Hodgkin Lym... Plasma Cell Mye... Lymphoid Leukem... Myeloid Leukemi... Myelodysplastic... Multiple Myelom... | Behavioral tech... | 18 Years - 74 Years | University of Wisconsin, Madison | |
| Outcomes in Pediatric and Young Adult B-Cell Malignancies After Commercially Available Immunotherapy | NCT05865301 | Lymphoid Leukem... | Questionnaire f... | - 26 Years | Stanford University | |
| Healthy Bones, Healthy Life: Habitual Physical Activity on Bone & Metabolic Health in Pediatric Cancer Survivors | NCT04472286 | Acute Lymphobla... Pediatric ALL Pediatric Lymph... Bone Loss Metabolic Syndr... Habitual Physic... Precursor Cell ... Lymphoma Leukemia Lymphoid Leukem... Pediatric Osteoporosis Osteoporosis Ri... | 5 Years - 18 Years | University of Nebraska | ||
| Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL | NCT01754857 | Lymphoid Leukem... Small Lymphocyt... Lymphoma, Non-H... | Bendamustine Rituximab Lenalidomide | 18 Years - | University of Wisconsin, Madison | |
| Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy | NCT00469729 | Hematologic Mal... Acute Myeloid L... Lymphoid Leukem... Chronic Myeloid... Hodgkin's Disea... Non-Hodgkin's L... Myelodysplastic... | StemEx® | 12 Years - 55 Years | Gamida Cell -Teva Joint Venture Ltd. | |
| Outcomes in Pediatric and Young Adult B-Cell Malignancies After Commercially Available Immunotherapy | NCT05865301 | Lymphoid Leukem... | Questionnaire f... | - 26 Years | Stanford University | |
| Integrated Actionable Aging Assessment for Cancer Patients Pilot | NCT05871008 | Breast Cancer Hodgkin Lymphom... Kidney Cancer Leukemia Lymphoid Leukem... Multiple Myelom... Myeloid Leukemi... Monocytic Leuke... Prostate Cancer Bladder Cancer | Assessment tool... Assessment tool... | 65 Years - 111 Years | University of Colorado, Denver | |
| A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas | NCT03277729 | Recurrent B-Cel... Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Refractory B-Ce... Refractory Diff... Refractory Foll... Refractory Lymp... Refractory Mant... Refractory Tran... Recurrent Trans... Recurrent Trans... Refractory Marg... Refractory Tran... Refractory Tran... Recurrent Small... Refractory Chro... Refractory Smal... Recurrent Centr... Refractory Cent... | Chimeric Antige... Cyclophosphamid... Laboratory Biom... Leukapheresis Fludarabine Pho... | 18 Years - | Fred Hutchinson Cancer Center | |
| Arsenic Trioxide for Induction Therapy of Adult Patients With Leukemia | NCT00006092 | Leukemia | Arsenic Trioxid... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas | NCT03277729 | Recurrent B-Cel... Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Refractory B-Ce... Refractory Diff... Refractory Foll... Refractory Lymp... Refractory Mant... Refractory Tran... Recurrent Trans... Recurrent Trans... Refractory Marg... Refractory Tran... Refractory Tran... Recurrent Small... Refractory Chro... Refractory Smal... Recurrent Centr... Refractory Cent... | Chimeric Antige... Cyclophosphamid... Laboratory Biom... Leukapheresis Fludarabine Pho... | 18 Years - | Fred Hutchinson Cancer Center | |
| Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL) | NCT01520922 | Chronic Lymphoc... Leukaemia, Lymp... | Ofatumumab Bendamustine | 18 Years - | Novartis | |
| T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies | NCT00683046 | Acute Myelogeno... Lymphoid Leukem... Chronic Myeloge... Malignant Lymph... Hodgkin's Disea... Chronic Lymphoc... Myeloproliferat... Anemia, Aplasti... Myelodysplastic... | Fludarabine Melphalan Stem cells Campath | - 100 Years | University of Chicago | |
| Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia | NCT03575325 | Lymphoid Leukem... Acute Lymphobla... Refractory Acut... Relapsed Acute ... | CPX-351 | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT04155840 | Lymphoid Leukem... Non-Hodgkin's L... Chronic Lymphoc... Small Lymphocyt... | Copanlisib Rituximab Bendamustine | 65 Years - | University of Washington | |
| Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS) | NCT03970096 | Acute Leukemia Acute Lymphobla... Acute Myeloid L... Myelodysplastic... | Total-Body Irra... Thiotepa Fludarabine Tacrolimus Allogeneic CD34... Methotrexate Cyclophosphamid... Peripheral Bloo... Cyclosporine Sirolimus Busulfan Bone Marrow Asp... Echocardiograph... Multigated Acqu... Biospecimen Col... | 1 Year - 60 Years | Fred Hutchinson Cancer Center | |
| Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia | NCT03575325 | Lymphoid Leukem... Acute Lymphobla... Refractory Acut... Relapsed Acute ... | CPX-351 | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies | NCT00683046 | Acute Myelogeno... Lymphoid Leukem... Chronic Myeloge... Malignant Lymph... Hodgkin's Disea... Chronic Lymphoc... Myeloproliferat... Anemia, Aplasti... Myelodysplastic... | Fludarabine Melphalan Stem cells Campath | - 100 Years | University of Chicago | |
| Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL) | NCT01520922 | Chronic Lymphoc... Leukaemia, Lymp... | Ofatumumab Bendamustine | 18 Years - | Novartis | |
| Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL | NCT01754857 | Lymphoid Leukem... Small Lymphocyt... Lymphoma, Non-H... | Bendamustine Rituximab Lenalidomide | 18 Years - | University of Wisconsin, Madison | |
| Therapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant Recipients | NCT03613727 | Lymphoid Leukem... Myeloid Leukemi... Monocytic Leuke... Myelodysplasia | Intravenous (IV... | 18 Years - 77 Years | Virginia Commonwealth University | |
| Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT04155840 | Lymphoid Leukem... Non-Hodgkin's L... Chronic Lymphoc... Small Lymphocyt... | Copanlisib Rituximab Bendamustine | 65 Years - | University of Washington | |
| Integrated Actionable Aging Assessment for Cancer Patients Pilot | NCT05871008 | Breast Cancer Hodgkin Lymphom... Kidney Cancer Leukemia Lymphoid Leukem... Multiple Myelom... Myeloid Leukemi... Monocytic Leuke... Prostate Cancer Bladder Cancer | Assessment tool... Assessment tool... | 65 Years - 111 Years | University of Colorado, Denver | |
| Biobehavioral Intervention to Enhance Hematopoietic Stem Cell Transplant Recovery | NCT02955043 | Hodgkin Lymphom... Non-Hodgkin Lym... Plasma Cell Mye... Lymphoid Leukem... Myeloid Leukemi... Myelodysplastic... Multiple Myelom... | Behavioral tech... | 18 Years - 74 Years | University of Wisconsin, Madison | |
| Healthy Bones, Healthy Life: Habitual Physical Activity on Bone & Metabolic Health in Pediatric Cancer Survivors | NCT04472286 | Acute Lymphobla... Pediatric ALL Pediatric Lymph... Bone Loss Metabolic Syndr... Habitual Physic... Precursor Cell ... Lymphoma Leukemia Lymphoid Leukem... Pediatric Osteoporosis Osteoporosis Ri... | 5 Years - 18 Years | University of Nebraska |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
